黑色素瘤脑转移局部治疗后辅助全脑放疗对比观察的III期随机试验
这项多中心随机III期试验纳入215例经局部治疗1-3个黑色素瘤脑转移的患者,随机接受辅助全脑放疗或观察。
要点
- 辅助全脑放疗未改善远处颅内控制、生存或体能状态。
- 全脑放疗与更多1-2级急性毒性相关。
核心结论
- 黑色素瘤脑转移局部治疗后辅助全脑放疗在远处颅内控制、生存或体能状态保持方面未提供临床获益。
研究设计与样本
- 多中心随机III期试验,2009年4月至2017年9月从24个中心随机分配215例经局部治疗1-3个黑色素瘤脑转移的患者至全脑放疗或观察组。
- 中位随访48.1个月(范围39.6-68个月)。
关键数值与推荐
- 主要终点为12个月内远处颅内失败,次要终点包括至颅内失败时间、生存和至体能状态恶化时间。
临床怎么用
- 对于1-3个黑色素瘤脑转移局部治疗后患者,不推荐常规使用辅助全脑放疗以改善远处颅内控制或生存。
局限性
- 全脑放疗与更多1-2级急性毒性相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The brain is a common site of metastasis for patients with high-risk melanoma. Although surgery or stereotactic radiosurgery are highly effective local treatments for a small number of metastases, there is a high risk of developing additional brain metastases. The role of adjuvant whole-brain radiotherapy (WBRT) in reducing new metastases is controversial, with a lack of high-level evidence specifically for melanoma. METHODS: In this randomized phase III trial, patients who had local treatment of one to three melanoma brain metastases were randomly assigned to WBRT or observation. The primary end point was distant intracranial failure within 12 months, and secondary end points included time to intracranial failure, survival, and time to deterioration in performance status. RESULTS: Between April 2009 and September 2017, 215 patients were randomly assigned from 24 centers. Median follow-up was 48.1 months (range, 39.6 to 68 months). Forty-two percent of patients in the WBRT group and 50.5% of those in the observation developed distant intracranial failure within 12 months (odds ratio, 0.71; 95% CI, 0.41 to 1.23; P = .22) and the rates over the entire follow-up period were 52.0% and 57.9%, respectively (odds ratio, 0.79; 95% CI, 0.45 to 1.36; P = .39). Local failure rate was lower after WBRT (20.0% v 33.6%; P = .03). At 12 months, 41.5% of patients in the WBRT group and 51.4% of patients in the observation group had died (P = .28), with no difference in the rate of neurologic death. Median time to deterioration in performance status was 3.8 months after WBRT and 4.4 months with observation (P = .32). WBRT was associated with more grade 1 to 2 acute toxicity. CONCLUSION: After local treatment of one to three melanoma brain metastases, adjuvant WBRT does not provide clinical benefit in terms of distant intracranial control, survival, or preservation of performance status.
引用
- Hong AM, Fogarty GB, Dolven-Jacobsen K, et al. Adjuvant Whole-Brain Radiation Therapy Compared With Observation After Local Treatment of Melanoma Brain Metastases: A Multicenter, Randomized Phase III Trial. J Clin Oncol. 2019. PMID: 31553661. doi:10.1200/JCO.19.01414
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。